Shattuck Labs (STTK) Projected to Post Quarterly Earnings on Wednesday

Shattuck Labs (NASDAQ:STTK) is expected to be announcing its earnings results on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $1.00 million for the quarter.

Shattuck Labs Stock Up 6.2 %

STTK stock opened at $1.37 on Monday. The firm has a market capitalization of $65.40 million, a PE ratio of -0.90 and a beta of 1.70. Shattuck Labs has a twelve month low of $0.94 and a twelve month high of $11.76. The stock has a 50-day simple moving average of $1.19 and a two-hundred day simple moving average of $1.84.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on STTK shares. HC Wainwright reaffirmed a “neutral” rating on shares of Shattuck Labs in a report on Friday, November 15th. Needham & Company LLC reiterated a “hold” rating on shares of Shattuck Labs in a research report on Thursday, November 14th. Four equities research analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $8.67.

Insider Activity

In other Shattuck Labs news, Director Redmile Group, Llc purchased 133,371 shares of the company’s stock in a transaction dated Wednesday, December 4th. The stock was purchased at an average price of $1.25 per share, for a total transaction of $166,713.75. Following the transaction, the director now owns 5,539,724 shares in the company, valued at $6,924,655. The trade was a 2.47 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 10.50% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.